Selfapy is a digital medical company founded in Berlin in 2016 by Nora Blum, Katrin Bermbach and Farina Schurzfeld. Selfapy develops digital health applications, such as online courses, that are aimed at people with mild to moderate depression.
The company’s online platform is based on the methods of cognitive behavioural therapy (CBT), with the mission of supporting people with mental health issues while making psychological support accessible to everyone, anywhere. With 40,000 users so far and over 25 psychologists working with the platform, Selfapy raises awareness of the issues around mental health and works to destigmatize the illness.
Recently, Selfapy completed a financing round of over €7 million, gaining a strong partner as an investor in Medice Arzneimittel, a family-run pharmaceutical company focused on treating ADHD. All existing investors were also involved, including the healthcare investors SHS, Think.Health Ventures, IBB Ventures and HTGF. The funding will be used for further growth in Germany and Europe.
Nora Blum, Co-CEO and founder of Selfapy, commented, “the financing round is an important milestone and a confirmation of the confidence in Selfapy’s success.”
The capital provided is intended to serve the development of further digital health applications for various mental diseases and growth in the German market. Another part of the capital is to be used for market entry in other European countries.
Adham Kassab, Co-CEO of Selfapy, said, “we see great potential for digital therapies in the field of mental illness both in Germany and internationally. With five completed RCT studies and a broad user base in Germany, we are on track to broaden our offering to more indications and expand into other markets.”
Dr. Richard Ammer, CEO of Medice, explained, “the strong development of Selfapy in recent years speaks for itself. Digital health applications will continue to gain in importance in the coming years. We continue to see a lot of growth potential here and look forward to accompanying Selfapy on this path.”
Selfapy’s permanently listed online courses for people with depression and anxiety disorders have already been reimbursed by all health insurance companies. The background is the certification of the therapy courses as digital health applications (DiGA), which are permanently listed in the directory of the Federal Ministry for Drugs and Medical Devices (BfArM).
Source: Selfapy
